Cannabis Consumption and Driving Impairment Assessment on a Closed Course
Study Details
Study Description
Brief Summary
In a true experiment, roughly 300 volunteer participants will smoke active cannabis, a corresponding placebo, or no substance at all (control). Next, participants will complete a drive test and then be observed by actual California Highway Patrol (CHP) officers who will attempt to classify participants as impaired or unimpaired. CHP Officers will evaluate participants in the context of driving (i.e., while following participants in an actual patrol car), as part of a roadside behavioral assessment (i.e., the Advanced Roadside Impaired Driving Enforcement, or ARIDE, battery, which includes Standardized Field Sobriety Tests, or SFSTs), and as part of a Drug Recognition Expert (DRE) evaluation conducted indoors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The easing of restrictions on the use of cannabis for recreational purposes presents a new challenge for policing of impaired driving, which is to say Driving Under the Influence of Drugs (DUI-D), specifically cannabis. In particular, it is not entirely clear how well the tools used by law enforcement officers to detect driving impairment (e.g., behavioral instruments such as the SFSTs, as included in the ARIDE battery) work for identifying cannabis-induced driving impairment specifically. While these instruments are designed to help officers identify driving impairment in general (irrespective of cause), prior empirical validation work has almost exclusively involved alcohol-induced impairment. This study will be conducted within a realistic, closed-course driving environment and it seeks to validate the same instruments currently used by law enforcement to detect cannabis-induced driving impairment against a second, independent, behavioral standard for driving impairment: a comprehensive driver evaluation adapted from the same set of driver tests that Californians must pass upon application for an original license, or (in certain instances) when referred to the Department of Motor Vehicles (DMV) for evaluation of their ability to safely operate a non-commercial class of motor vehicle (here referred to as the Modified Driver Performance Evaluation or MDPE).
This study seeks to answer the following research questions:
-
How accurately do behavioral assessments used by officers distinguish between drivers impaired by cannabis and drivers not impaired by cannabis?
-
How does cannabis affect real-world (as opposed to simulated) driving performance?
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Active Smoked Cannabis Participants in this arm will smoke an active cannabis cigarette containing 18.16% Δ9-tetrahydrocannabinol (THC). The smoking will occur at each participant's preferred pace, but will be limited to a maximum ten-minute period. While individual doses vary in this type of paradigm (ad libitum dosing), the anticipated dose of THC within the cannabis condition can be approximated by the following formula: (700 mg of cannabis) x [% of cigarette smoked; maximum of 70% (allowing room to hold the cigarette)] x (% THC). Therefore, the maximum dose in this arm is 700 mg x 70% x 18.2% = 89.18 mg of THC. Individual participants will only take part in the study under a single condition and receive the active cannabis once. Bulk cannabis for this arm will be provided by the National Institute on Drug Abuse Drug Supply Program; cannabis cigarettes will be prepared and prescribed by the Research Pharmacy of the University of California, San Diego. |
Drug: Active smoked cannabis
Assessment of active cannabis smoking and driving impairment
Other Names:
|
| Placebo Comparator: Placebo Smoked Cannabis Participants in this arm will smoke a placebo cannabis cigarette containing <.01 THC. The smoking will occur at each participant's preferred pace, but will be limited to a maximum ten-minute period. Individual participants will only take part in the study under a single condition and receive the placebo cannabis once. Bulk placebo for this arm will be provided by the National Institute on Drug Abuse Drug Supply Program; placebo cannabis cigarettes will be prepared and prescribed by the Research Pharmacy of the University of California, San Diego. |
Drug: Placebo smoked cannabis
Assessment of placebo cannabis smoking and driving impairment
Other Names:
|
| No Intervention: Control Participants in this arm receive no cannabis. Individual participants will only take part in the study under a single condition. |
Outcome Measures
Primary Outcome Measures
- Modified Driving Performance Examination (MDPE) [Conducted an average of 35 minutes after the assigned intervention is completed.]
The MDPE driving test, developed for this study, is administered once per participant per experimental session. It occurs after the assigned intervention (i.e., drug administration) and it is primarily scored dichotomously (pass versus fail).
- Advanced Roadside Impaired Driving Enforcement (ARIDE) battery [Conducted an average of 65 minutes after the assigned intervention is completed.]
The ARIDE battery is not a scale but a series of roadside behavioral assessments used by law enforcement officers to help them detect impaired driving: (1) pulse check, (2) Horizontal Gaze Nystagmus or HGN, (3) a test of distinct and sustained nystagmus, (4) vertical nystagmus, (5) lack of convergence test, (6) a check to see if eyes are bloodshot or watery, (7) Modified Romberg Balance Test, (8) Walk and Turn Test or WAT, (9) One Leg Stand Test or OLS, and some additional observations. The ARIDE battery occurs once per participant following the Modified Driving Performance Examination. The ARIDE battery is scored overall as pass versus fail by the officer conducting the test (in real-time).
- Drug Recognition Expert (DRE) evaluation [Conducted an average of 90 minutes after the assigned intervention is completed.]
The DRE evaluation is designed to help law enforcement officers identify whether an individual is generally impaired and, if so, which class of substance caused the impairment. The DRE evaluation occurs once per participant, following the ARIDE battery. It is scored by the officer conducting it in real-time as a judgment about state of impairment (impaired versus unimpaired), and, in the case of impairment, a judgment about the class of substance.
Secondary Outcome Measures
- First blood draw (baseline) [Conducted 15 minutes before the assigned intervention.]
The first blood sample is collected at baseline (after consent procedures and a medical checkup), roughly 25 minutes into the experimental session. This is before the assigned intervention (i.e., drug administration) and before any of the primary outcome measures occurs. All samples will undergo toxicological analyses to assess blood concentrations (in nanograms per milliliter) of cannabinoids, as well as the presence of other drugs (opioids, benzodiazepines, and stimulants).
- Second blood draw (change from baseline) [Conducted immediately after the assigned intervention is completed.]
The second blood sample is collected immediately after the assigned intervention (i.e., drug administration), around the time that THC concentration is expected to be at its peak. Most samples will undergo toxicological analyses to assess blood concentrations (in nanograms per milliliter) of cannabinoids and these results will be compared to those of the first blood draw. In the case of control participants whose first sample did not reveal the presence of cannabinoids, no further analyses will be conducted.
- Third blood draw (change from baseline and second blood draw) [Conducted an average of 85 minutes after the assigned intervention is completed.]
The third blood sample is collected after the Advanced Roadside Impaired Driving Enforcement (ARIDE) battery and immediately before the Drug Recognition Expert (DRE) evaluation. Most samples will undergo toxicological analyses to assess blood concentrations (in nanograms per milliliter) of cannabinoids and these results will be compared to those of the first and second blood draws. In the case of control participants whose first sample did not reveal the presence of cannabinoids, no further analyses will be conducted.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Possessing a valid California driver's license
-
Cannabis use in the past six months
-
Willing and able to abstain from alcohol, cannabis, and other recreational drugs for 24 hours prior to scheduled participation
-
Willing and able to avoid driving and operating heavy machinery for at least four hours after participation
-
Residence within approximately 15 miles of the study site
-
Possessing the capacity to provide informed consent
Exclusion Criteria:
-
Completion of a roadside sobriety test during the previous 12 months
-
Physical or psychological conditions that can be exacerbated by cannabis use, or for which cannabis use is contraindicated
-
Potential presence of Cannabis Use Disorder as assessed by a modified version of the Cannabis Use Disorder Identification Test
-
Potential presence of Substance Use Disorder as assessed by a modified version of the Drug Abuse Screening Test
-
Pregnancy or breastfeeding reported
-
Unwillingness to be transported by taxi
-
Having been convicted of Driving Under the Influence (DUI) within five years prior to scheduled participation
-
Parole or probation status
-
One or more felony convictions on record involving aggressive or dangerous criminal activity
-
Any of the following at the time of the experimental session: breath alcohol content of .01% or greater; positive pregnancy test; cannabis consumption considered unsafe following medical checkup by the study nurse; or driving test behavior considered hazardous by the driving examiner
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | California Department of Motor Vehicles Headquarters | Sacramento | California | United States | 95818-2606 |
Sponsors and Collaborators
- Bayliss J. Camp, PhD
Investigators
- Principal Investigator: Bayliss J Camp, PhD, California Department of Motor Vehicles
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 19C066000